VBL First-in-class MOSPD2 Antibodies Show Potential for Treatment for CNS Inflammation
May 04 2020 - 7:00AM
VBL Therapeutics (Nasdaq: VBLT) is pleased to announce the
publication of a new manuscript demonstrating the potential of
MOSPD2 antibodies for Multiple Sclerosis (MS). VBL's data offer a
differentiated approach to potential treatment of central nervous
system (CNS) inflammatory diseases using MOSPD2 antibodies that
inhibit monocyte migration. Currently, there are no approved
therapies for MS that target monocyte migration.
VBL's data show that knockout of the MOSPD2 gene in
mice essentially protected the animals from developing CNS disease
in the well-established EAE model for MS. Proprietary anti-MOSPD2
antibodies that block monocyte migration without affecting T-cells,
were able to recapitulate this effect and profoundly reduced
inflammation and tissue damage.
"The data emphasize how important monocytes are in
regulating the chronicity of inflammation in this MS model," said
Itzhak Mendel, Ph.D., Immunology Director of VBL Therapeutics and
lead author of the paper. "Our antibodies reduced disease severity
not only as a preventive treatment, but also when administered as
treatment for established disease. This opens us opportunities for
potential treatment of relapsing as well as progressive MS disease,
in which there is a major unmet need."
VBL is advancing lead candidate antibody VB-601
towards a first-in-man study, which is expected in 2021. For VBL's
open-access manuscript, see: LINK.
About VBL's VB-600 Platform
VBL is conducting two parallel drug development
programs that are exploring the potential of MOSPD2, a protein that
VBL has identified as a key regulator of cell motility, as a
therapeutic target for inflammatory diseases and cancer. Our VB-600
platform comprises classical anti-MOSPD2 monoclonal antibodies for
inflammatory indications, as well as bi-specific antibody
candidates for oncology.
About VBLVascular Biogenics Ltd.,
operating as VBL Therapeutics, is a clinical stage
biopharmaceutical company focused on the discovery, development and
commercialization of first-in-class treatments for cancer. VBL’s
lead oncology product candidate, ofranergene obadenovec (VB-111),
is a first-in-class, targeted anti-cancer gene-therapy agent that
is being developed to treat a wide range of solid tumors. It is
conveniently administered as an IV infusion once every two months.
It has been observed to be well-tolerated in >300 cancer
patients and demonstrated activity signals in a VBL-sponsored “all
comers” phase 1 trial as well as in three VBL-sponsored
tumor-specific phase 2 studies. Ofranergene obadenovec is currently
being studied in a VBL-sponsored phase 3 potential registration
trial for platinum-resistant ovarian cancer.
Forward Looking Statements This
press release contains forward-looking statements. All statements
other than statements of historical fact are forward-looking
statements, which are often indicated by terms such as
“anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,”
“intend,” “look forward to,” “may,” “plan,” “potential,” “predict,”
“project,” “should,” “will,” “would” and similar expressions. These
forward-looking statements may include, but are not limited to,
statements regarding our programs, including VB-600, including
their clinical development, therapeutic potential and clinical
results. These forward-looking statements are not promises or
guarantees and involve substantial risks and uncertainties. Among
the factors that could cause actual results to differ materially
from those described or projected herein include uncertainties
associated generally with research and development, clinical trials
and related regulatory reviews and approvals, the risk that
historical clinical trial results may not be predictive of future
trial results, that our financial resources do not last for as long
as anticipated, and that we may not realize the expected benefits
of our intellectual property protection. A further list and
description of these risks, uncertainties and other risks can be
found in our regulatory filings with the U.S. Securities and
Exchange Commission, including in our annual report on Form 20-F
for the year ended December 31, 2019, and subsequent filings
with the SEC. Existing and prospective investors are cautioned
not to place undue reliance on these forward-looking statements,
which speak only as of the date hereof. VBL
Therapeutics undertakes no obligation to update or revise the
information contained in this press release, whether as a result of
new information, future events or circumstances or otherwise.
INVESTOR CONTACT:Michael
RiceLifeSci Advisors, LLC(646) 597-6979
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From Apr 2023 to Apr 2024